Monopar Therapeutics Inc

General ticker "MNPR" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $828.1M

Monopar Therapeutics Inc follows the US Stock Market performance with the rate: 37.6%.

Estimated limits based on current volatility of 10.5%: low 24.17$, high 29.83$

Factors to consider:

  • Current price 661.2% above estimated high
  • Earnings for 9 months up through Q3 are below our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2023-12-31 to 2025-12-30

  • 2023-12-31 to 2024-12-30 estimated range: [0.95$, 3.15$]
  • 2024-12-30 to 2025-12-30 estimated range: [1.07$, 3.25$]

Financial Metrics affecting the MNPR estimates:

  • Negative: Non-GAAP EPS, $ of -2.57 <= 0.10
  • Negative: Operating profit margin, % of -100 <= 1.03
  • Negative: Operating cash flow per share per price, % of -23.88 <= 2.35
  • Negative: negative Net income
  • Positive: Inventory ratio change, % of 0 <= 0
  • Negative: Industry earnings per price (median), % of -26.04 <= 1.31
  • Positive: Interest expense per share, $ of 0 <= 0

Similar symbols

Short-term MNPR quotes

Long-term MNPR plot with estimates

Financial data

YTD 2021-12-31 2022-12-31 2023-12-31
Operating Revenue $0.00MM $0.00MM $0.00MM
Operating Expenses $9.13MM $10.54MM $8.83MM
Operating Income $-9.13MM $-10.54MM $-8.83MM
Non-Operating Income $0.02MM $0.04MM $0.43MM
R&D Expense $6.49MM $7.59MM $5.60MM
Income(Loss) $-9.10MM $-10.50MM $-8.40MM
Profit(Loss) $-9.10MM $-10.50MM $-8.40MM
Stockholders Equity $18.94MM $10.09MM $5.59MM
Assets $20.52MM $13.23MM $7.35MM
Operating Cash Flow $-7.32MM $-7.23MM $-7.86MM
Investing Cash Flow $0.00MM $-4.92MM $4.93MM
Financing Cash Flow $10.88MM $0.03MM $2.03MM
Earnings Per Share* $-0.73 $-0.83 $-0.58

* EPS are Split Adjusted, recent splits may be reflected with a delay.